A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

After surviving a stage four diagnosis, an Illinois realtor is sharing her story to encourage others not to ignore the ...

While both are called medullary carcinoma, these cancers differ in many ways: ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12, ...